Literature DB >> 33512356

[Real-world evidence vs EBM: what does real-world data add?]

Matteo Franchi1, Giovanni Corrao1.   

Abstract

Although randomized clinical trials (RCTs) offer the highest level of scientific evidence, they are unable to evaluate the impact of treatments in the routine clinical practice. The heterogeneity of socio-demographic and clinical characteristics of patients, as well as the complexity of treatments, explain the gap between the effect observed in RCTs and its impact in the real-world setting. As compared to conventional trials, pragmatic RCTs are conducted in a setting as similar as possible to that of clinical practice, but they are not always able to narrow this gap. For this reasons, methods aimed to produce evidence on the impact of healthcare pathways in the real-world (i.e., real-world evidence) are of growing interest. In particular, those based on the Electronic Healthcare Utilization (EHU), including administrative databases on the healthcare services provided to beneficiaries of the National Health System, are receiving increasing consideration from both the scientific community and healthcare decision-makers. In this article, we described characteristics and research areas where EHU databases may be particularly useful, along with strengths and limits of this approach. In conclusion, EHU data should not replace RCTs, but they represent a powerful tool for integrating RCTs and for supporting healthcare decision-makers.

Entities:  

Mesh:

Year:  2021        PMID: 33512356     DOI: 10.1701/3525.35121

Source DB:  PubMed          Journal:  Recenti Prog Med        ISSN: 0034-1193


  1 in total

1.  MEALTIME BOLUS INSULIN DOSE TIMING IN CHILDREN WITH TYPE 1 DIABETES: REAL-LIFE DATA FROM A TERTIARY CARE CENTRE IN NORTHERN INDIA.

Authors:  L Rohilla; D Dayal; N Gujjar; P Walia; R Kumar; J Yadav
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Oct-Dec       Impact factor: 1.104

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.